期刊文献+

HPLC法测定卡巴拉汀贴剂中药物含量及其体外透皮释放量分析

下载PDF
导出
摘要 目的:用高效液相色谱(HPLC)法测定卡巴拉汀贴剂中药物含量及其体外透皮释放量。方法:采用Franz扩散池,用离体豚鼠皮肤为透皮屏障固定在扩散池上部,取卡巴拉汀贴剂,揭去防粘层贴于皮肤角质层上。以pH值为6.8的磷酸盐缓冲溶液为透皮释放接收介质,进行HPLC分析,结果:卡巴拉汀贴剂标定含量为4.5mg,检测结果为4.45mg;卡巴拉汀体外透皮释放量在9.7~116.02g/mL浓度范围内线性关系良好,高、中、低3个浓度的平均回收率分别为99.79%、98.62%、98.58%。结论:使用高效液相色谱(HPLC)法测定卡巴拉汀贴剂中药物含量及其体外透皮释放量操作简便,且灵敏度和准确性高,可有效测定卡巴拉汀贴剂的中药物含量及其体外透皮释放量。
作者 王建祥
出处 《中国中医药咨讯》 2011年第15期241-242,共2页
  • 相关文献

参考文献4

二级参考文献12

  • 1KARTHIK A,SUBRAMANIAN GS,SURULIVELRAJAN M ,et al. Fluorimetric determination of rivastigmine in rat plasma by a reverse phase-High performance liquid chromatographic method-Application to a pharmacokinetie study [J]. Arzneimittelforschung, 2008,58(5) :205 -210.
  • 2[1]Meiran N, Stuss DT, Guzman DA, et al. Diagnosis of dementia:Methods for interpretation of scores of 5 neuropsychological test.Arch Neurol, 1996,53 (10): 1043.
  • 3[2]Rosler M, Anand R, Cicin - Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer' s disease: international randomized controlled trial. BMJ, 1999,318 (7184) :633.
  • 4[3]Risse SC, Raskind MA, Nochlin D,et al. Neuropathological findings in patients with clinical diagnoses of probable Alzheimer's disease. Am J Psychiatry,1990,147(2) :168.
  • 5[4]Shadlen MF, Larson EB. What' s new in Alzheimer' s disease treatment:Reasons for optimism about future pharmacologic options. Postgrad Med,1999,105(1): 109.
  • 6[5]Maire JC,Wurtman RJ. Choline production from choline -containing phospholipids: a hypothetical role in Alzheimer' s disease and aging. Prog Neuropsychopharmacol Biol Psychiatry, 1984,8(4 -6) :637.
  • 7[6]Guillozet AL, Mesulam MM, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Anu Neurol, 1997,42 (6):909.
  • 8[7]Lamb HM, Goa KL. Rivastigmine:a pharmacoeconomic review of its use in Alzheimer' s disease. Can J Neurol Sci,2001,28 (Suppl 1) :S122.
  • 9[8]Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.. Arch Neurol ,2001,58 (3) :417.
  • 10[9]Sramek JJ, Anand R, Wardle TS,et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci, 1996,58 ( 15 ): 1201.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部